Maroxim (Dronabinol, Cannabidiol)

Maroxim combines dronabinol and cannabidiol and is employed in conditions where modulation of the endocannabinoid system can provide therapeutic benefit.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea episodes.
• HIV/AIDS‑related weight loss: stimulates appetite and promotes weight gain.
• Chronic pain: offers analgesic relief in patients with refractory pain.

• Dronabinol and cannabidiol act as partial agonists at cannabinoid receptors CB1 and CB2. Activation of CB1 in the central nervous system modulates neurotransmitter release, producing anti‑emetic, analgesic and appetite‑stimulating effects, while CB2 activation influences immune and inflammatory pathways, contributing to overall symptom control.

Maroxim may cause a range of adverse reactions, most of which are related to its cannabinoid activity.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Dry mouth: reduced salivation leading to throat discomfort.
• Fatigue: feeling unusually tired or weak.
• Somnolence: increased sleepiness, especially after dosing.
• Changes in appetite: either increased or decreased food intake.
• Mild hypotension: slight drop in blood pressure causing faintness.

Serious or Rare Side Effects

• Severe hypotension: marked blood‑pressure decline requiring medical attention.
• Psychosis or hallucinations: altered perception or mental status changes.
• Respiratory depression: reduced breathing effort, particularly with high inhaled doses.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Cannabinoid hyperemesis syndrome: recurrent vomiting episodes.
• Seizures: rare neurologic events, especially in predisposed individuals.

When prescribing Maroxim, clinicians should consider several safety aspects.

• Pregnancy: safety not established; avoid use unless benefits outweigh risks.
• Respiratory disorders: use caution in patients with COPD or asthma.
• Concomitant CNS depressants: monitor for additive sedation or respiratory effects.
• History of psychosis: avoid or use with close supervision.
• Driving and machinery: advise patients not to operate vehicles or heavy equipment while impaired.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Maroxim can interact with other medicines through metabolic pathways and central nervous system effects.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation or respiratory depression.
• Alcohol: enhances central effects and may impair coordination.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Antihypertensives: additive hypotensive effect, monitor blood pressure.
• Other cannabinoids or CBD products: may increase side‑effect burden.